Inventiva announces major recruitments to accelerate the development of lanifibranor in NASH
16 sept. 2021 16h00 HE
|
INVENTIVA
Seven recruitments with solid track records and complementary profiles to reinforce Inventiva’s clinical expertise, medical team and corporate functions New recruitments further expand the Company’s...
Présentation des résultats financiers du 1er semestre 2021 d’Inventiva
10 sept. 2021 09h00 HE
|
INVENTIVA
Daix (France), le 10 septembre 2021 – Inventiva (Euronext Paris et Nasdaq : IVA), société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par voie orale...
Inventiva’s 2021 First-Half Financial Results Presentation
10 sept. 2021 09h00 HE
|
INVENTIVA
Daix (France), September 10, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment...
Inventiva annonce le lancement de l’étude clinique pivot de Phase III évaluant lanifibranor dans la NASH
08 sept. 2021 16h00 HE
|
INVENTIVA
Ouverture des premiers sites cliniques et début du screening des patientsL’étude clinique de Phase III NATiV3 se déroulera en deux parties et évaluera l'efficacité et la tolérance à long terme de...
Inventiva announces the initiation of its pivotal Phase III clinical trial evaluating lanifibranor in NASH
08 sept. 2021 16h00 HE
|
INVENTIVA
Activation of first clinical sites and start of patient screeningThe two-part NATiV3 Phase III clinical trial will evaluate the long-term efficacy and safety of lanifibranor in adult patients with...